Corus CAD

Latest Headlines

This spring, CardioDx had readied itself again to make a run at an IPO. But it's opted to take another round of private investment instead. It has raised $35 million in equity from new investor Alberta Investment Management alongside existing investors.

CardioDx, the heart disease test developer that delayed plans to go public in November due to poor market conditions, has decided to test the IPO waters again. This time it will be doing it with some new leadership.

CardioDx, a cardiovascular genomic diagnostics company, pulled in an impressive $58 million in new equity financing in a massive round that attracted a Singapore investment firm and lured 14 previous backers.